Roger Nitsch

USPTO Granted Patents = 28 (Patent Applications = 27)

CIPO Patents = 6 (Patent Applications = 2)

EPO Patents = 12 (Patent Applications = 20)

Average Co-Inventor Count = 5.4

ph-index = 8

Forward Citations = 160(Granted Patents)

Location History:

Zollikon, CH (2003 - 2009)
Zumikon, CH (2011 - 2022)

Company Filing History:

Biogen International Neuroscience Gmbh

patents

3 out of 16

Neurimmune Holding Ag

patents

4. 2 out of 2

Biogen Idec International Neuroscience Gmbh

Delenex Therapeutics Ag

patents

7. 1 out of 149

Boehringer Ingelheim Pharma Kg

patents

8. 1 out of 3

Nsc Therapeutics Gmbh

where one patent can have more than one assignee

Years Active: 2003-2025

Loading Chart...

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12201619 - Compounds and methods for use in the treatment of microglia-mediated disorders (2025-01-21),

2. 11352441 - Human anti-SOD1 antibodies (2022-06-07),

3. 11091540 - TDP-43 specific binding molecules (2021-08-17),

4. 10874725 - Method of providing patient specific immune response in amyloidoses and protein aggregation disorders (2020-12-29),

5. 10703808 - Human anti-alpha-synuclein antibodies (2020-07-07),

6. 10344097 - Human anti-SOD1 antibodies (2019-07-09),

7. 10301381 - Anti-alpha synuclein binding molecules (2019-05-28),

8. 10259866 - TDP-43 specific binding molecules (2019-04-16),

9. 10202445 - Method of providing disease-specific binding molecules and targets (2019-02-12),

10. 10131708 - Methods of treating Alzheimer's disease (2018-11-20),

11. 9975947 - Anti-alpha synuclein binding molecules (2018-05-22),

12. 9896504 - Human anti-alpha-synuclein antibodies (2018-02-20),

13. 9828420 - Method of providing disease-specific binding molecules and targets (2017-11-28),

14. 9670272 - Method of providing disease-specific binding molecules and targets (2017-06-06),

15. 9605059 - Human anti-tau antibodies (2017-03-28),

Title: Unveiling the Innovative Journey of Roger Nitsch

Introduction:

Roger Nitsch, a visionary inventor hailing from Zumikon, Switzerland, has left an indelible mark on the world of inventions with his groundbreaking work. His relentless pursuit of innovation has resulted in numerous patents that have advanced the fields of medicine and biomedical research.

Latest Patents:

Among Roger Nitsch's impressive portfolio of 27 patents are two notable creations: Human anti-SOD1 antibodies and TDP-43 specific binding molecules. These inventions revolutionize the fields of immunotherapy and diagnostics, offering new avenues for treating diseases linked to these proteins.

Career Highlights:

Roger Nitsch's illustrious career includes collaborations with prestigious institutions such as the University of Zurich and Biogen International Neuroscience GmbH. His research and discoveries have significantly contributed to the understanding and treatment of neurodegenerative disorders.

Collaborations:

Throughout his career, Roger Nitsch has worked closely with accomplished colleagues such as Jan Grimm and Christoph Hock. Their combined expertise and dedication have led to innovative solutions that have the potential to reshape the landscape of modern medicine.

Conclusion:

In conclusion, Roger Nitsch stands as a beacon of creativity and ingenuity in the world of inventions, with his work continuing to inspire future generations of inventors and innovators. His groundbreaking patents not only showcase his technical prowess but also underline his commitment to pushing the boundaries of scientific discovery. Roger Nitsch's contributions serve as a testament to the transformative power of innovation in driving progress and improving lives worldwide.

This text is generated by artificial intelligence and may not be accurate.